A Phase 3 clinical trial of Annovis Bio‘s investigational oral treatment buntanetap in people with early-stage Parkinson’s disease now will open to patients in Europe. This expansion will add 48 new trial sites in Italy, Spain, Hungary, Poland and Germany, joining about 50 sites actively recruiting in the U.S.
A small group of people with Parkinson’s disease adhered well to an experimental music-based digital therapy to treat gait problems, and reported quality of life gains, meeting the main goals of a small feasibility trial, according to its developer MedRhythms. Preliminary evidence of the trial (NCT04891107) that…
The American Parkinson Disease Association (APDA) will host a free, two-day virtual conference for people with Parkinson’s disease and their caregivers on February 15–16. The program is scheduled to run from 12 p.m. to 3:30 p.m. EST each day. “The APDA Virtual Parkinson’s Conference will include an…
High-frequency stimulation of both the brain’s primary motor cortex (M1) and its dorsolateral prefrontal cortex (DLPFC) — two regions with altered activity in Parkinson’s disease — may be the optimal use of transcranial magnetic stimulation (TMS) in easing Parkinson’s motor symptoms, a meta-analysis study reported. In analyzing data from…
Researchers have developed a video-based algorithm to predict the severity of tremor in Parkinson’s disease patients based on the criteria of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). The new algorithm was found to identify tremors, both resting and postural, with high accuracy — ranging from…
Annovis Bio anticipates an interim data analysis from a Phase 3 trial of its therapeutic candidate buntanetap in people with early-stage Parkinson’s disease will be possible by mid-year, based on current trial enrollment. By then, there will likely be enough patients who’ll have received at least two months…
People with REM sleep behavior disorder (RBD) — an early nonmotor symptom of Parkinson’s disease — were significantly more likely than others to wrongly think their sense of smell was normal when olfactory deficits were evident, a small study found. Parkinson’s patients with RBD also had a diminished sense…
A 12-week electroacupuncture (EA) regimen in Parkinson’s disease patients along with standard medications was well tolerated and led to improved motor function and some relief from constipation, a recent study showed. Patients also reported gains in quality of life compared with those only receiving standard of care medications. “Our…
Neurocrine Biosciences has acquired rights to Voyager Therapeutics’ experimental gene therapy program for Parkinson’s disease associated with mutations in the GBA1 gene and for other GBA1-mediated diseases. The collaboration agreement also includes three gene therapy programs for rare diseases of the central nervous system (CNS;…
One year of treatment with Duopa, a levodopa/carbidopa intestinal gel, led to fast and sustained reductions in motor fluctuations and improved symptom control throughout the day among people with advanced Parkinson’s disease. That’s according to new analyses of data from a earlier large-scale Phase 3 clinical trial that…
Get regular updates to your inbox.